Relevant bibliographies by topics / Pharmaceutical Benefits Scheme (Australia)

Academic literature on the topic 'Pharmaceutical Benefits Scheme (Australia)'

Author: Grafiati
Published: 4 June 2021
Last updated: 28 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Pharmaceutical Benefits Scheme (Australia).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Pharmaceutical Benefits Scheme (Australia)"

1

Harvey, Ken. "Australia: Pharmaceutical Benefits Scheme." Lancet 337, no. 8738 (February 1991): 418–19. http://dx.doi.org/10.1016/0140-6736(91)91181-s.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Graham, David. "The Australian Pharmaceutical Benefits Scheme." Australian Prescriber 18, no. 2 (April 1, 1995): 42–44. http://dx.doi.org/10.18773/austprescr.1995.049http://www.australianprescriber.com/magazine/18/2/42/4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Turkstra, Erika, Emilie Bettington, Maria L. Donohue, and Merehau C. Mervin. "PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE RECOMMENDATIONS IN AUSTRALIA." International Journal of Technology Assessment in Health Care 33, no. 4 (2017): 521–28. http://dx.doi.org/10.1017/s0266462317000617.

Full text
Abstract:
Objectives: The aim of this study was to examine submissions made to the Pharmaceutical Benefits Advisory Committee (PBAC) and assess whether the predicted financial impact was associated with a recommendation. The second objective was to assess whether the financial and utilization estimates for listing the proposed medicine were reliable.Methods: Data were extracted from public summary documents of major submissions considered by the PBAC from 2012 to 2014. Information collected included whether submissions were accepted, rejected, or deferred; estimated use; and financial impact. For those submissions that were recommended in 2012 and listed on the Pharmaceutical Benefits Scheme (PBS) by January 2014, a comparison was made between predicted and actual use and cost in 2014, based on PBS utilization.Results: In 2012 to 2014, the PBAC considered 142 unique major submissions; of those, 65 were recommended for listing. A higher financial cost to the government was a statistically significant factor in predicting rejection (p = .004 for cost > AUD 30 million Australian dollars [20.7 million Euros] compared with cost-saving). Of the submissions that were recommended in 2012 and listed by 2014, the actual use was higher than predicted for 5/19 medications. The estimated cost was outside the predicted bracket of cost for 10/19 medications, with 8/19 medications having threefold underestimated expenditure, and 2/19 items having lower than predicted expenditure.Conclusions: This study highlights that the predicted financial impact of a medication to the PBS budget is associated with a PBAC recommendation and also highlights that predicted use may not reflect actual prescribing practices.
APA, Harvard, Vancouver, ISO, and other styles
4

Harvey, Ken. "Correction: Patents, pills and politics: the Australia-United States Free Trade Agreement and the Pharmaceutical Benefits Scheme." Australian Health Review 28, no. 3 (2004): 381. http://dx.doi.org/10.1071/ah040381.

Full text
Abstract:
Re: ?Patents, pills and politics: the Australia? United States Free Trade Agreement and the Pharmaceutical Benefits Scheme?, by Ken Harvey, (Aust Health Rev 2004, vol. 28, no. 2, pp. 218-226). Under the heading ?A brief history of patent law relevant to pharmaceuticals?, in the second paragraph, the second sentence was: ?Before TRIPS, many developing countries provided no patent protection on pharmaceutical products, or they recognised patents on products but not process?. The corrected version should be ?. . .process but not products?.
APA, Harvard, Vancouver, ISO, and other styles
5

Harvey, Ken. "Patents, pills and politics: the Australia–United States Free Trade Agreement and the Pharmaceutical Benefits Scheme." Australian Health Review 28, no. 2 (2004): 218. http://dx.doi.org/10.1071/ah040218.

Full text
Abstract:
There is tension between the need of the pharmaceutical innovator for intellectual property protection and the need of society for equitable and affordable access to innovative drugs. The recent Australia?United States Free Trade Agreement provides a nice illustration of this interplay between patents, pills and politics. This article provides a brief history of patent law as applied to pharmaceuticals, describes how the Pharmaceutical Benefits Scheme got caught up in AUSFTA negotiations, analyses the clauses that are likely to impact upon the PBS and describes the political process that reviewed and ultimately amended the AUSFTA.
APA, Harvard, Vancouver, ISO, and other styles
6

Robertson, Jane, Emily J. Walkom, and David A. Henry. "Transparency in pricing arrangements for medicines listed on the Australian Pharmaceutical Benefits Scheme." Australian Health Review 33, no. 2 (2009): 192. http://dx.doi.org/10.1071/ah090192.

Full text
Abstract:
Australia?s system for assessing the cost-effectiveness of drugs for listing under the Pharmaceutical Benefits Scheme (PBS) is recognised internationally. A variety of mechanisms, such as evidencebased rules for determining eligibility for initial or continuing subsidy, price-volume agreements, rebates, and caps on government expenditure are used to contain PBS expenditures. In this paper we assess the extent of use of special pricing arrangements in Australia and how and where they are communicated to health professionals and the community. We searched publicly available documents published by the Pharmaceutical Benefits Advisory Committee (PBAC) and the Pharmaceutical Benefits Pricing Authority (PBPA). We found 73 medicines where special pricing arrangements had been applied and where prices appearing on the Schedule of Pharmaceutical Benefits might differ from those considered to be ?cost-effective? by the PBAC. Reporting of these special pricing agreements was inconsistent and generally non-transparent. In some, the lack of transparency may have reflected the desire of manufacturers to disguise the true negotiated price, lest it weaken their negotiation position in other jurisdictions.
APA, Harvard, Vancouver, ISO, and other styles
7

Faunce, Tom. "How the Australia-US free trade agreement compromised the pharmaceutical benefits scheme." Australian Journal of International Affairs 69, no. 5 (July 7, 2015): 473–78. http://dx.doi.org/10.1080/10357718.2015.1048785.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Adams, Robert J., Sarah Appleton, David H. Wilson, Anne W. Taylor, Catherine Chittleborough, Tiffany Gill, and Richard E. Ruffin. "Cholesterol-lowering therapy and the Australian Pharmaceutical Benefits Scheme: a population study." Australian Health Review 33, no. 2 (2009): 325. http://dx.doi.org/10.1071/ah090325.

Full text
Abstract:
Objective: The Australian Pharmaceutical Benefits Scheme (PBS) expanded the criteria for eligibility for subsidised lipid-lowering therapy (LLT) in 2006. The aim of this study was to determine the use of LLT in a representative Australian population in relation to cardiovascular disease (CVD) risk, and the effectiveness of the therapy in meeting target levels. Design: Cross-sectional biomedical study with telephone interviews, questionnaires, clinical measurements, and PBS dispensing data. Subjects: Representative population sample of 4060 urban adults aged 18 years attending for the biomedical examination in 2001. Results: Of the 406 who qualified for PBS-subsidised LLT at that time, only 88 (21.5%) were actually on LLT. National Heart Foundation of Australia (NHF) recommended low-density lipoprotein cholesterol (LDL-C) levels of < 2.5 mmol/L were recorded in only 13% (528) of the population, and in 46.8% of those on LLT. Of those on LLT, 76% had total cholesterol < 5.5 mmol/L, but over 80% had total cholesterol levels above NHF-recommended levels of 4.0 mmol/L. Of the 842 classified at the highest CVD risk, only 26% were using LLT. Those aged > 60 years and on low incomes were significantly more likely to use LLT. The new PBS criteria will expand eligibility to include nearly 20% of adults. Conclusions: The majority of people at high risk of CVD were not receiving LLT, and LLT is not being used to its full effectiveness. People with low incomes or on government benefits or pensions were not less likely to use LLT than others under the PBS scheme. Whether higher copayments for those on low incomes who do not qualify for concessional payments is a significant barrier to LLT use needs further research.
APA, Harvard, Vancouver, ISO, and other styles
9

Doran, Evan, Jane Robertson, and Glenn Salkeld. "Pharmaceutical Benefits Scheme cost sharing, patient cost consciousness and prescription affordability." Australian Health Review 35, no. 1 (2011): 37. http://dx.doi.org/10.1071/ah10902.

Full text
Abstract:
Objective. To assess patients’ prescription medicine cost consciousness and explore the implications of further cost sharing increases for affordability. Design and participants. A telephone interview survey of 818 randomly selected prescription medicine users (408 concession card holders, 410 general beneficiaries) resident in the Hunter Valley region of New South Wales, Australia. Main outcome measures. Degree of prescription cost consciousness; attitudes towards prescription use and cost sharing; self-rated capacity to manage further co-payment increases and differences between concession card holders and general beneficiaries in these measures. Results. The majority of participants were cost conscious medicine users who act responsibly towards medicine use and believe that cost sharing is appropriate. Although there were no differences in cost consciousness scores, card holders appeared more sensitive to prescription costs and increases. Conversely, general beneficiaries were more likely to report difficulties with cost (avoiding seeing a doctor, not collecting prescription medicines, stopping or reducing the dose of a prescribed medicine). Although almost 75% of respondents reported that a co-payment increase would cause financial difficulty, only 28% indicated this would change their medicine use. Conclusions. These results suggest that most Australian patients are cost conscious but many are also close to facing difficulties with prescription costs. Further increases in PBS cost sharing could compromise prescription affordability, particularly for general beneficiaries. What is known about the topic? Increased PBS cost sharing is intended to minimise unnecessary demand for prescription medicines while maintaining affordability. The key mechanism to achieve this – ‘cost consciousness’ – has not been investigated. What does this paper add? The paper provides patient level data on cost consciousness, attitudes to cost sharing and patient capacity to manage future increases in PBS cost sharing. What are the implications for practitioners? Australians are cost conscious. Further increases in PBS cost sharing make some patients even more cost conscious but may also erode affordability, particularly for general beneficiaries. A review of cost sharing is important and long overdue.
APA, Harvard, Vancouver, ISO, and other styles
10

Harvey, Ken J., Thomas A. Faunce, Buddhima Lokuge, and Peter Drahos. "Will the Australia–United States Free Trade Agreement undermine the Pharmaceutical Benefits Scheme?" Medical Journal of Australia 181, no. 5 (September 2004): 256–59. http://dx.doi.org/10.5694/j.1326-5377.2004.tb06264.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Pharmaceutical Benefits Scheme (Australia)"

1

Sweeny, Kim. "Accounting for growth in the Pharmaceutical Benefits Scheme." full-text, 2008. http://eprints.vu.edu.au/1960/1/sweeny.pdf.

Full text
Abstract:
This thesis investigates the contribution to the growth in expenditure on medicines listed on the Pharmaceutical Benefits Scheme (PBS) from three inter-related sources: (i) the addition of new medicines offering an expanding range of treatments for disease, (ii) PBS processes for determining the prices of medicines and their conditions of listing and (iii) the demand by patients for PBS medicines. In doing so it uses trend analysis presented in both tabular and graphic form, expenditure decomposition techniques based on index and indicator numbers, and econometric analysis. Using novel techniques and interpretations, it addresses some key aspects of decomposition analysis including the treatment of new and disappearing goods and the potential bias arising from changing market shares among substitutable medicines. The analysis is undertaken for the period from 1991-92 to 2005-06. An important consequence of the cost-effectiveness and reference pricing techniques used by the PBS, is that the quantity index calculated within the decomposition of PBS expenditure can be interpreted as a measure of the quality-adjusted amount of medicines consumed by patients. This is virtually equivalent to the growth in expenditure of about 12% per annum. On average prices of medicines fell over time, modestly in nominal terms and to a greater extent in real terms. Based on the results of econometric analysis, new evidence is presented on the relative influences of copayments, safety net limits, the number of PBS medicines listed and their conditions of listing on the demand for PBS medicines by different categories of patients. Elasticities with respect to patient price are in the range -1.1 to -1.4 for General Non-Safety Net patients and in the range -0.5 to -0.9 for Concessional Non-Safety Net patients.
APA, Harvard, Vancouver, ISO, and other styles
2

Sweeny, Kim. "Accounting for growth in the Pharmaceutical Benefits Scheme." Thesis, full-text, 2008. https://vuir.vu.edu.au/1960/.

Full text
Abstract:
This thesis investigates the contribution to the growth in expenditure on medicines listed on the Pharmaceutical Benefits Scheme (PBS) from three inter-related sources: (i) the addition of new medicines offering an expanding range of treatments for disease, (ii) PBS processes for determining the prices of medicines and their conditions of listing and (iii) the demand by patients for PBS medicines. In doing so it uses trend analysis presented in both tabular and graphic form, expenditure decomposition techniques based on index and indicator numbers, and econometric analysis. Using novel techniques and interpretations, it addresses some key aspects of decomposition analysis including the treatment of new and disappearing goods and the potential bias arising from changing market shares among substitutable medicines. The analysis is undertaken for the period from 1991-92 to 2005-06. An important consequence of the cost-effectiveness and reference pricing techniques used by the PBS, is that the quantity index calculated within the decomposition of PBS expenditure can be interpreted as a measure of the quality-adjusted amount of medicines consumed by patients. This is virtually equivalent to the growth in expenditure of about 12% per annum. On average prices of medicines fell over time, modestly in nominal terms and to a greater extent in real terms. Based on the results of econometric analysis, new evidence is presented on the relative influences of copayments, safety net limits, the number of PBS medicines listed and their conditions of listing on the demand for PBS medicines by different categories of patients. Elasticities with respect to patient price are in the range -1.1 to -1.4 for General Non-Safety Net patients and in the range -0.5 to -0.9 for Concessional Non-Safety Net patients.
APA, Harvard, Vancouver, ISO, and other styles
3

Donnelly, Neil James Public Health &amp Community Medicine Faculty of Medicine UNSW. "The use of interrupted time series analysis to evaluate the impact of Pharmaceutical Benefits Scheme policies on drug utilisation in Australia." Awarded by:University of New South Wales. Public Health and Community Medicine, 2005. http://handle.unsw.edu.au/1959.4/22509.

Full text
Abstract:
PROBLEM INVESTIGATED: Methodological issues and policy implications arising from the application of interrupted time series (ITS) analyses to assess the impact of Pharmaceutical Benefit Scheme (PBS) subsidisation policies on drug utilisation in Australia. PROCEDURES FOLLOWED: A critical review of methodological issues relating to the application and analysis of ITS designs was undertaken. This included an examination of drug utilisation data sources in Australia. The PBS policies examined were: (i) the introduction of copayments in 1990; (ii) the introduction of re-supply limits in 1994 and (iii) the introduction of a form of reference pricing in 1998. Monthly aggregate drug utilisation data was obtained from the Australian Department of Health and Ageing. Segmented regression analyses incorporating autocorrelated errors were implemented and statistical diagnostics applied to ensure correct ITS model specification. Alternative seasonal modelling approaches were compared. RESULTS OBTAINED: The copayment ITS evaluation found that while these copayments produced a reduction in the utilisation of essential and discretionary medications, this effect was stronger for discretionary drugs. An unintended policy effect was a large anticipatory increase in drug utilisation during the month prior to the copayments. Repatriation PBS data was also utilised due to the limited number of pre-intervention data points in the Community series. The re-supply limit ITS evaluation found that the 20-day rule markedly reduced the size of the seasonal increase during the month of December. However, logistic regression analyses showed that the size of this reduction attenuated over time, highlighting the need to consider alternative analysis strategies when applying a ITS approach. The reference pricing ITS evaluation found that this policy had achieved its drug utilisation objectives for H2RAs and ACE Inhibitors. However with regard to CCBs, no increase in the utilisation of benchmark priced drug was apparent, which probably reflected clinical concerns at the time about the safety of these drugs. MAJOR CONCLUSIONS: Well implemented ITS analyses provide a valuable tool for evaluating the impact of PBS subsidisation policy change on drug utilisation in Australia. As with any methodology, however, different design and data integrity issues will affect the quality of information provided.
APA, Harvard, Vancouver, ISO, and other styles
4

Lee, Kah Seng. "The impact of cost containment reforms to the Pharmaceutical Benefits Scheme (PBS) on prescribing volumes and expenditure in Australia: 1992-2011." Thesis, Curtin University, 2014. http://hdl.handle.net/20.500.11937/836.

Full text
Abstract:
Objectives: To investigate the impact of cost containment measures on PBS prescribing volumes and expenditure. Methods: Segmented linear regression models were used to analyse the time series data from Medicare Australia’s PBS Statistics. Seven measures and four new listing dates of statins were investigated. Results: Many of the cost containment measures were effective in containing costs. Conclusions: The safety net 20 days rule was estimated to be the most effective in reducing drugs utilisation and expenditure.
APA, Harvard, Vancouver, ISO, and other styles
5

Schofield, Deborah, and n/a. "Modelling health care expenditure : a new microsimulation approach to simulating the distributional impact of the Pharmaceutical Benefits Scheme." University of Canberra. Information Sciences & Engineering, 1999. http://erl.canberra.edu.au./public/adt-AUC20061107.171802.

Full text
Abstract:
In this thesis, a microsimulation model was developed using methods which were intended to overcome the main criticism of earlier models developed in Australia - that their estimation of the distribution of health benefits1 across income groups was not accurate. To determine whether the new model � called the Person Level Model of Pharmaceutical Benefits (PLM-PB) � was more accurate, two typical means-based models were also built to replicate the most commonly used methods in Australia. A comparison of the results of the three models revealed that while they produced comparable results at the aggregate when compared with administrative data, the PLM-PB was much more accurate in capturing distributional differences by beneficiary and medication type. The PLM-PB also indicated that, as anticipated, PBS benefits were more pro-poor than earlier means-based models had suggested. The PLM-PB had another important advantage in that the method also captured the variation in the use of medication and thus the subsidy received within sub-populations. As the PLM-PB was found to be more accurate than the means-based model, a multivariate analysis of the distribution of PBS subsidy across a number of socio-economic groups was undertaken as an example application of the model. It was found that health status (defined by number of recent illnesses) and concession card type were most important in explaining the amount of PBS subsidy received. This indicates that the distribution of PBS expenditure meets the policy objectives of assisting those most in need, whether need is defined as poor health or low income. 1 Benefits refer to expenditure as transfers from government to individuals rather than the general health benefits of using medication.
APA, Harvard, Vancouver, ISO, and other styles
6

Georgiou, Jonathan. "Exploring the benefits of attracting, recruiting and retaining mature age employees up to and beyond the traditional age of retirement: Perspectives from Western Australia." Thesis, Edith Cowan University, Research Online, Perth, Western Australia, 2015. https://ro.ecu.edu.au/theses/1632.

Full text
Abstract:
There has been a recent upsurge in media attention surrounding Australia’s ageing workforce. A review of academic, media and grey literature highlighted inadequacies in existing workplace polices, as well as flaws in financial and social security schemes. Of particular concern were persistent negative attitudes and counterproductive policies regarding mature age employees (MAEs). Poor retention rates among this cohort of workers aged 45 years and over are leading to skilled labour shortages and losses in corporate knowledge. This expected mass exodus of mature cohorts into retirement has been predicted to negatively impact the socio-economic sustainability of ageing societies world-wide and is a pertinent issue for Western Australia (WA). The overarching objective of this study was to identify the ‘place’ of mature cohorts within WA workplaces and promote strategies that will improve the employment conditions and overall quality of life of ageing workforces. Research questions aimed to address the need for greater mature age employment up to and beyond pensionable age; identify ‘gaps’ in policies and programmes; and explore how mature cohorts were perceived (valued) and the extent their departure may affect WA society (labour force). By using a mixed methods research design, this Doctoral dissertation developed a conceptual framework for limiting significant issues individuals, businesses and society may experience as a result of WA’s ageing workforce; whilst simultaneously promoting the benefits of maturity and mature age employment. This Re-Model draws upon the community development work principles of social justice, empowerment and social capital; and is further contextualised by methods of best practice identified from the triangulation of secondary sources, quantitative data and qualitative inquiry. Primary data collection involved the completion of 362 surveys, followed by 27 semistructured interviews and four focus group activities, with a cross section of MAEs, volunteers, their employers, retirees and unemployed cohorts from across WA. Over one-third of current MAEs, employers and volunteers in this study reported they intended working later than the traditional age of retirement, with 71 per cent of this sample planning to semi-retire. Furthermore, almost 60 per cent of a sample that had previously exited the labour force was working at the time of data collection as semi-retirees or rehired retirees (rehirees). Collectively, these statistics indicated that despite predictions of mass disengagement among mature cohorts, most of this crosssection of Western Australians are seeking to remain in (or re-enter) the WA workforce beyond pensionable age. However, quantitative and qualitative findings revealed several barriers to their continued engagement, including access to ‘age-friendly’ workplaces; a dearth of targeted training (career) development and employment assistance; and a lack of value attributed to mature age skills and experience, particularly deleterious in WA’s youth-centric culture. Primary data also highlighted several enabling factors for mature age employment. ‘Flexibility’ and ‘autonomy of choice’ were cited as key dimensions across all aspects of paid work, volunteering and retirement – whether in terms of worklife- balance; the individuation of training and development; or options available to those transitioning out of traditional employment. Data indicated that sustainable cultural change required more than just the removal of negative policies or introduction of punitive legislation. Maintaining a positive outlook among mature age individuals and simultaneously educating (younger) co-workers, employers, policy-makers (stakeholders) and society about the virtues of maturity and non-traditional work (skills) were considered essential to changing societal attitudes, behaviour and culture.
APA, Harvard, Vancouver, ISO, and other styles
7

Lu, Christine Yi-Ju Medical Sciences Faculty of Medicine UNSW. "An examination of systems of access to important high cost medicines: a critical analysis of the nationally subsidised scheme of access to tumour necrosis factor inhibitors in Australia." 2007. http://handle.unsw.edu.au/1959.4/40579.

Full text
Abstract:
Background: Access to " high-cost medicines" under Australia's Pharmaceutical Benefits Scheme (PBS) is characterised by strict eligibility criteria. The PBS access scheme for the anti-rheumatic biologicals (etanercept, infliximab, and adalimumab) was examined for concordance with Australia?s National Medicines Policy. Methods: Semi-structured interviews with a range of stakeholders were conducted. National, aggregated prescription and expenditure data from Medicare Australia and dispensing data from the Drug Utilisation Sub-Committee were analysed. Access to biologicals was also examined from an ethical perspective. Results: Interviewees agreed that controlled access to high-cost medicines was broadly equitable and practical but specific concerns included: timeliness of access; bureaucracy of the process; contentious cases of individual patients being denied access; insufficient patient information; the quantum of resources required to administer the access scheme; inadequate stakeholder consultation. The access requirement of a history of failure of conventional anti-rheumatic drugs was supported. Recommendations included proactive review of the access criteria and outcomes; greater transparency and formal stakeholder involvement to increase public confidence in the definition of " target patient population" and a formal appeal mechanism to increase the fairness and accountability of the PBS. Establishment of an appeal mechanism is supported by " accountability for reasonableness" framework grounded in procedural justice. Data needed to examine the health outcomes associated with the use of biologicals on a national level was not easily available. This shortcoming is discordant with National Medicines Policy. Utilisation of biologicals over the first two years of PBS-subsidy was conservative but with considerable variability across States and Territories (an 8-fold difference between the jurisdictions), usage roughly correlating with access to rheumatologists. Introduction of PBS-subsidised biologicals did not alter the trends in utilisation of non-biological anti-rheumatic drugs. Conclusions: This research suggests that policy-makers focus upon: explicitly considering ethical principles and formally involving stakeholders when developing policies on access to high-cost medicines; improving communication and providing information based on increased transparency; and establishing formal mechanisms for review of and appeals against PBS decisions. The comprehensive evaluation of medicine use and outcomes post-subsidy is critical for the future of the PBS. The National Medicines Policy has proved a useful framework for evaluating this access scheme.
APA, Harvard, Vancouver, ISO, and other styles
8

Neville, Warwick John. "Healing the nation : access to medicines under the Pharmaceutical Benefits Scheme - the jurisprudence from history." Phd thesis, 2007. http://hdl.handle.net/1885/150188.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Mak, Christine Suet Yee. "Evaluation of health programs: application of social cost benefit analysis in the Pharmaceutical Benefits Scheme listing of Australia." Thesis, 2005. https://vuir.vu.edu.au/15635/.

Full text
Abstract:
The integration of economics and moral philosophy, which provides a new approach to evaluation and analysis of economic activities, is increasing within the literature. It is argued in this thesis that valuation and analysis in health economics and health programs (normative health economics) should be based on these recent advances. However, an appropriate integration of moral philosophy in the area of health economics has not yet been done. The objectives of this thesis are to modify the existing economic theory of health analysis by integrating the issues and principles of moral philosophy and develop some operational mathematical models to show how the proposed framework for integration of moral philosophy in the area of health economics can be applied to health economics and policy evaluation.
APA, Harvard, Vancouver, ISO, and other styles
10

Searles, Andrew. "A preliminary analysis of the pharmaceutical provisions in the Australia-United States Free Trade Agreement on prescription medicines in Australia." Thesis, 2010. http://hdl.handle.net/1959.13/44658.

Full text
Abstract:
Research Doctorate - Doctor of Philosophy (PhD)
In January 2005 Australia implemented the Australia-United States Free Trade Agreement (AUSFTA). The AUSFTA was a historic document because it laid out a closer trading association between Australia and its close ally, the United States (US). The Agreement was generally welcomed in both countries but it contained provisions that were controversial, perhaps none more so than those covering pharmaceuticals. In Australia there was deep concern over the effects of these provisions on the Pharmaceutical Benefits Scheme (PBS). A Senate Committee investigating the likely impact of the AUSFTA was apprehensive that the provisions would result in the PBS paying higher prices for some medicines. The many outcomes from the research reported in this thesis are preliminary but amongst them, three stood out. First, the AUSFTA instituted a number of small but significant changes to Australian pharmaceutical policies and processes. Some changes, around transparency and listing times, were positive while others, such as sponsor hearings before the PBAC, will probably have limited negative impact. Second, there is now a need to consider the AUSFTA commitments when Australian health policy is reassessed in the future, which will now make Australia’s regulatory processes more complex. Third, it is argued that the AUSFTA may have had input into major reforms of the Australian PBS. These reforms delivered on an outcome that had been sought by the US: a weakening of reference pricing as used by the Australian PBS. The benefit from the change to reference pricing for Australia is unclear, but the PBS is now more vulnerable to higher prices for new medicines in the future.
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Pharmaceutical Benefits Scheme (Australia)"

1

Office, New Zealand Audit. Department of Health: Administration of the pharmaceutical benefits scheme. Wellington, N.Z: The Office, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Australia. Dept. of Finance. and Australian National Audit Office, eds. Joint review by the Auditor-General and the Department of Finance: Pharmaceutical benefits scheme, review of estimated savings from proposed system for eligibility checking. Canberra: Australian Govt. Pub. Service, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Zealand, New. Department of Health: Administration of the pharmaceutical benefits scheme. The Office, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Schweitzer, Stuart O., and Z. John Lu. Economic Evaluation of New Drugs. Oxford University Press, 2018. http://dx.doi.org/10.1093/oso/9780190623784.003.0009.

Full text
Abstract:
As a result of new cost-containment incentives found in both public and private healthcare plans, providers and insurers are subjecting new healthcare services, and especially pharmaceuticals, to evaluations in which costs and benefits are explicitly compared. Collectively, this body of work is referred to as health technology assessment. This chapter discusses in detail the three methodologies most frequently utilized in HTA: cost-benefit analysis, cost-effectiveness analysis, and cost-utility analysis. The appropriate roles for each of these approaches and examples of their applications in several influential HTA organizations around the world are elaborated, including the National Institute for Health and Care Excellence in the UK, the Pharmaceutical Benefits Advisory Committee in Australia, and the Canadian Agency for Drugs and Technologies in Health. The history and current state of HTA in the United States is also examined in the chapter.
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Pharmaceutical Benefits Scheme (Australia)"

1

Epp, Joanne, Bonny Parkinson, and Sally Hawse. "Health System Sustainability: The Pharmaceutical Benefits Scheme in Australia." In Industry and Higher Education, 13–44. Singapore: Springer Singapore, 2020. http://dx.doi.org/10.1007/978-981-15-0874-5_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Karanges, Emily A., Melisa J. Litchfield, Leigh Mellish, and Sallie-Anne Pearson. "The Australian Pharmaceutical Benefits Scheme (PBS) Dispensing Database." In Databases for Pharmacoepidemiological Research, 255–66. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-51455-6_21.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Jackson, John. "Pharmaceutical Benefits Scheme (Australia)." In Encyclopedia of Clinical Pharmacy (Print), 688–91. CRC Press, 2002. http://dx.doi.org/10.1201/b13789-119.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Jackson, John K. "Pharmaceutical Benefits Scheme (Australia)." In Encyclopedia of Clinical Pharmacy, 688–91. Informa Healthcare, 2002. http://dx.doi.org/10.3109/9780824706081.118.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Löfgren, Hans, and Ken Harvey. "The Pharmaceutical Benefits Scheme." In Understanding the Australian Health Care System, 71–82. Elsevier, 2009. http://dx.doi.org/10.1016/b978-0-7295-3861-9.10007-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Zeimer, Henry. "Australia." In Dementia Care: International Perspectives, 109–14. Oxford University Press, 2019. http://dx.doi.org/10.1093/med/9780198796046.003.0015.

Full text
Abstract:
Dementia is a major public health issue in Australia, with profound consequences for the healthcare system and society in general, with nearly 1.5% of the population living with dementia. It has wide-ranging effects on the healthcare system and society in general, and its prevalence is expected to increase significantly with the ageing of the population. Through the Medicare Benefits Schedule and the Pharmaceutical Benefits Scheme, the Australian government funds services for diagnosis and assessment, as well as subsidizing medications for the treatment of Alzheimer’s disease. The government also funds community support groups and services to assist in the care, and improve the quality of life, of people with dementia. The Australian Health Ministers announced in August 2012 that dementia is a National Health Priority Area, the ninth medical condition to receive this important status.
APA, Harvard, Vancouver, ISO, and other styles
7

Abello, Annie, and Laurie Brown. "Model 18 MediSim (Static Microsimulation Model of the Australian Pharmaceutical Benefits Scheme)." In Modelling our Future - Population Ageing, Health and Aged Care, 533–39. Elsevier, 2007. http://dx.doi.org/10.1016/s1571-0386(06)16037-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

de Boer, Rebecca. "Reform of the pharmaceutical benefits scheme." In Analysing Health Policy, 214–24. Elsevier, 2008. http://dx.doi.org/10.1016/b978-0-7295-3843-5.50017-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Lin, Chad, and Geoffrey Jalleh. "Evaluation of B2B Pharmaceutical Supply Chain in Australia." In Advances in E-Business Research, 56–79. IGI Global, 2015. http://dx.doi.org/10.4018/978-1-4666-8133-0.ch003.

Full text
Abstract:
The pharmaceutical industry is one of the most innovative and research-intensive industries in the world. For example, five out of the top global Research and Development (R&D) companies were pharmaceutical companies. However, the industry is lagging behind other industries in adopting Business-to-Business (B2B) and supply chain technologies. With supply chain costs constituting around 25-40% of an organization's operating expenses, it is imperative for senior pharmaceutical executives to minimize this cost. Hence, the main objective of this chapter is to identify key B2B e-commerce management, evaluation, and benefits realization factors and challenges within the Australian pharmaceutical supply chain. The results of this study suggest that pharmaceutical companies not only need to carefully examine their B2B investment management and evaluation practices but also must invest in using appropriate evaluation methodologies for identifying and managing benefits, risks, and costs associated with their investments in B2B and supply chains.
APA, Harvard, Vancouver, ISO, and other styles
10

"A War of Attrition: the Fate of the Pharmaceutical Benefits Scheme." In The Price of Health, 209–32. Cambridge University Press, 1991. http://dx.doi.org/10.1017/cbo9780511470189.010.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Pharmaceutical Benefits Scheme (Australia)"

1

Khan, Arif, Uma Srinivasan, and Shahadat Uddin. "Development and exploration of polymedication network from Pharmaceutical and Medicare Benefits Scheme data." In ACSW 2019: Australasian Computer Science Week 2019. New York, NY, USA: ACM, 2019. http://dx.doi.org/10.1145/3290688.3290738.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Pharmaceutical Benefits Scheme (Australia)' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography